PDF(Pubmed)
Abstract：
In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case-control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5-88.7) in the main analysis and 80.6% (61.6-90.3) and 80.4% (61.7-89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.
摘要：
2023年9月，法国是最早开始使用nirsevimab进行全国免疫运动的国家之一，一种新的抗呼吸道合胞病毒（RSV）的单克隆抗体。使用来自儿科重症监护病房（PICU）网络的数据，我们旨在评估nirsevimab对法国严重RSV毛细支气管炎的疗效.我们进行了一项基于测试阴性设计的病例对照研究，包括20个PICU报告的288名婴儿。我们在主要分析中估计nirsevimab的有效性为75.9％（48.5-88.7），在两次敏感性分析中估计为80.6％（61.6-90.3）和80.4％（61.7-89.9）。这些真实世界的估计证实了在临床研究中观察到的功效。
